Evidence map›Paper›PMID 38815289›Full record

ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2024

Novel high molecular weight polymerized hemoglobin in a non-obese model of cardiovascular and metabolic dysfunction.

Cynthia R Muller, Alexander T Williams, Allyn M Eaker, Cynthia Walser, Fernando Dos Santos, Clayton T Cuddington, Savannah R Wolfe, Andre F Palmer, Pedro Cabrales

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cynthia R MullerDepartment of Bioengineering, University of California, San Diego, CA, USA.
Alexander T WilliamsDepartment of Bioengineering, University of California, San Diego, CA, USA.
Allyn M EakerDepartment of Bioengineering, University of California, San Diego, CA, USA.
Cynthia WalserDepartment of Bioengineering, University of California, San Diego, CA, USA.
Fernando Dos SantosDepartment of Anesthesiology & Critical Care, University of California, San Diego, CA, USA.
Clayton T CuddingtonWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.
Savannah R WolfeWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.
Andre F PalmerWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA.
Pedro CabralesDepartment of Bioengineering, University of California, San Diego, CA, USA. Electronic address: pcabrales@ucsd.edu.

Funding

PEGylated megahemoglobin for use as a red blood cell substituteR01HL138116 · NHLBI · OHIO STATE UNIVERSITY · PI CABRALES, PEDRO, KAUMAYA, PRAVIN T. P. · 2017 to 2020
$2.9M
Bioengineering a Dual Function Protein Construct to Detoxify Heme and HemoglobinR01HL159862 · NHLBI · OHIO STATE UNIVERSITY · PI BUEHLER, PAUL WERNER, CABRALES, PEDRO · 2021 to 2024
$2.6M
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysisR01HL162120 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI BUEHLER, PAUL WERNER, CABRALES, PEDRO · 2022 to 2025
$2.6M
Attenuating the Oxidative and Myocardial Side-Effects of Acellular HemoglobinR01HL126945 · NHLBI · OHIO STATE UNIVERSITY · PI CABRALES, PEDRO, PALMER, ANDRE FRANCIS · 2016 to 2019
$1.7M
NHLBI NIH HHS R01 HL126945NHLBI NIH HHS R01 HL138116NHLBI NIH HHS R01 HL159862NHLBI NIH HHS R01 HL162120
6 · The paper itself

Abstract

The widespread adoption of high-calorie, high-fat, high-sucrose diets (HFHSD) has become a global health concern, particularly due to their association with cardiovascular diseases and metabolic disorders. These comorbidities increase susceptibility to severe outcomes from viral infections and trauma, with trauma-related incidents significantly contributing to global mortality rates. This context underscores the critical need for a reliable blood supply. Recent research has focused on high molecular weight (MW) polymerized human hemoglobin (PolyhHb) as a promising alternative to red blood cells (RBCs), showing encouraging outcomes in previous studies. Given the overlap of metabolic disorders and trauma-related health issues, it is crucial to assess the potential toxicity of PolyhHb transfusions, particularly in models that represent these vulnerable populations. This study evaluated the effects of PolyhHb exchange transfusion in guinea pigs that had developed metabolic disorders due to a 12-week HFHSD regimen. The guinea pigs, underwent a 20 % blood volume exchange transfusion with either PolyhHb or the lower molecular weight polymerized bovine hemoglobin, Oxyglobin. Results revealed that both PolyhHb and Oxyglobin transfusions led to liver damage, with a more pronounced effect observed in HFHSD-fed animals. Additionally, markers of cardiac dysfunction indicated signs of cardiac injury in both the HFHSD and normal diet groups following the Oxyglobin transfusion. This study highlights how pre-existing metabolic disorders can exacerbate the potential side effects of hemoglobin-based oxygen carriers (HBOCs). Importantly, the newer generation of high MW PolyhHb showed lower cardiac toxicity compared to the earlier generation low MW PolyhHb, known as Oxyglobin, even in models with pre-existing endothelial and metabolic challenges.

Indexed as

Cardiovascular DiseasesHemoglobinsMetabolic DiseasesMolecular WeightAnimalsBlood SubstitutesDiet, High-FatDisease Models, AnimalGuinea PigsHumansMaleBlood SubstitutesHemoglobinsHemoglobin-based oxygen carriersHigh-fat high sucrose dietMetabolic disordersOxygen therapeuticPolymerized hemoglobinRed blood cell substitute

Identifiers

PMID38815289
PMCPMC12885157

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.